Does carvedilol inhibit aortal smooth muscle cell proliferation?  by Mohacsi, P. et al.
JACC February I(F)X 469A 
culer evl~l~l This iS cormstent with recent study showing protechve effect of 
immunizing LDL r~mptor-deflcmnt rab~ts with OxLDL, 
~ ClmulMory Effo¢l~ of Nl¢orandll After Flint [lose 
and Alter Repeated Dosing 
U, Thadam. ~ ot O~. .a .  O~ahorna C~, O~a,  USA 
N~'ofalld;! (NIC) Is a ru¢otmama:le d(~ivatw~ (n,[~_ H y ~ ]  racottnam~:~te 
~rate), which m'~pmv~ (~mae/~ gow and m an ami~chem¢ agent, 
but tm~ke mwahm ~ ¢*mn',~d not to be mmocmte¢l wrm de',~lormment of
!n a ~ l~nd ram~mlzed CroSsover Mud~ m 14 paf~mts with ~ 
emgm~ pectoe~, eltects o! t 0 mg NIC o~ placelpo (PL) on ,~%'tJfl bk~x) pm~swe 
(~P) ~d bean ra~ m ~alualed Mter ~ f l~  d0se ar~ a:'.-xer 2 weeks 
dose. Comlmmd Io ~ vames changu ~n sysfo~ (S) ard ~ c  (d) 
BP and ~ mm (HR) m the ~ p0s~0n aftsr !1~ first (~R~ ~ after 
~ : .~ ,a  ol I~1 emramt were: 
! l-imm~ 4 Hours aHou~ 
N~C e~. mC ~ ~C PL 
(S|BPIstDO~e -2~" -3 -tg' 0 t6" -4 
D~tt4 -it -4 5 ~t2 -3 
(D)BPt=Do~ .-t3" -~ -t3" -i -~2 -5 
Day t4 -7 -3 -7 -4 -4 -2 
(HR) tslDo~e 12 1 3 4 2 3 
O~et4 3 -2 -5 4 4 S 
Dala show h'lat r.~t dose ol 10 mg NIC emptied s~mficant clmtdalory 
eltects Ira- at leas1 up to 8 houm b~ me peak ~,',~ct and du~a~ o~ effec~ 
m~re ~ ammuam~ am~ re~ea~m ~.  Thos. ~ ~o pmra~ 
v~ew, ll~s sludy shows that c ~  torrance dm¢=k~ps fogom~g ~ 
eq~sme to ntcorandd. 
What Ro~e Ooes Uann.ol may In PnmmU.g 
Commst ~ ?  a ~ Ana~ts 
KJ. Tobm. P.A. McCultough. J.P. Speck. D.C. Westveer, OA. Guido-Nten. 
O.S. I"lmleNm~, S.B. ~ . -Ochod0,  W.W_ O'Nei,, M. Stmmns. 
Diwskm of Cardiovascular Medich'm, Her~. Ford a~d Vascuiar lnst;r~ 
Hemy Fo.rl Heat~ b~.  One Ford mac~ S~te 3C, Detro~ Mt 48202. 
USA 
Rece~ ~ have shown ltmt ~ use of mannttot may mcm~se renal o~t- 
ge~ demands, and deslm~, causing an osmot¢ diurems, may be ,n]u.ou~ to 
renal ~ after vascular contrast exposure. It's use. ~-=mfom, as a l~ro- 
phytact¢ agent to prevent contrast ~ t h y  after coronary 
remains controvers,~. As part of the PRINCE (Prmmr~r~n of Rad~K:ormast 
Induced Nephropathy Evaluat~0n) Tnal. palmnts ~ were ~ to a 
forced dmmsLs protocol (fumsemide I mg/kg WP and dopamme 3.g/kg/mm 
IV) and had a mean pulmooary capdla~ wedge pmssu~ <20 mmHg at the 
sta~ ot the procedure, received intravenous marmitol 12.5 oj1~g over 2 I'mum 
This administmtmn occurred clunng ~e conlrasl exposure and was foffo~ed 
by Ii~lrahon with 0.5 NS IV at a rato to match the urine oulput. As dictated by 
the protocol, those who were selected for mam,lol had a k~er mean PCWP. 
14.4 vs. 26.1 mmHg. p = 0.0009. The mean baseline serum c1"eatimne (Cr) 
was 2.2 ± 0.38 vs. 2.59 ± 0.94 in the mannttokexpased (groc~ 1, n = 22) vs. 
the mannitol-unexposed (group 2. n = 76), p = 0.05. Groups 1 and 2 were 
othe~rise sin~lar with respect to confotmdem including diabetic status and 
contrast volume received. The mean induced urine flow rates were 167.62 
± 58.00 vs. 133.20 ± 55.63 mYmin/over 24 hours, p = 0.02, in groups 1 and 
2 r e ~ .  The resultant mean Cr at 48 houm after contrast exposure 
was 2.72 ~ 1.19 vs. 3.11 ± 1.21 mg/dl, p = 0.22, and the mean ~ 1  
increase in Cr was 0.61 ± 0.98 vs. 0.58 ± 0.72 mg/dl, p = 0.88, respectrvely. 
Conclusions: Despite its use in patients with mote favorable renal funchon 
and hemodyrmmic profiles, the controlled, pmspectnte IV administration of 
mannitol was not effectwe in preventing renal injury despite augmentato'~ of 
a forced diuresis with other agents. 
~ A Randomized "t~ial of  Prevention Measures in 
Patients at High Risk for Contrast Nephropathy: 
Initial Results of  the PRINCE Study 
M. Stevens, P.A. McCuilough, K.J. Tobin, J.P. Speck, D.C. Westveer, 
O.A, Guido-Allen, D.S. Hartenburg, S.B. Puchrowicz-Ochocki, W.W. O°Neig. 
Division of Cardiovascular Medicine, Henry Ford and Vascular Institute, 
Henry Ford Heaffh System, One Ford Place, Suite 3C, Detroit, M1482~.,2o • 
USA 
Recent studies from series of PTCA and CABG patients indicate that baseline 
renal o~furctmn m an indelmndem IXe<~cfor f monal~ after ~ ~,-~,. 
cl.res. We have pmv~usly tmown a gra0~l mlatmmm~ w~ me ¢ ~  ol 
renal failure and ~ Im:~l~y of m-homital death m Im,mn~ un(~ 
Io0p ~urel¢~, mannitol) have 8ho.~ no clear ~ ~ I 
of patmm= m r~m, We Nt  out t ~ ttm the ~ .,~t a fo¢=¢1 ¢~nm 
a~er me con.a~ e~Do~um w~h a ~ of me~ ~mu~ m~u~ m 
a mduce~ ~me c~ re.al U~r~ ,n ~ ~mm~ w e ~ m  
0,9 mg/~, The ~m~Im were ~,~lar with rL~xcl to age, W~l~ ~:~¢ 
edent 0t i~ml  vMctll~r ¢lileMe, The f0R~Kl ~tmm~ fwct~e¢l m 
um~ flow rallm, 1~3 ~ ~4 vs. I~3 ~ SS ml/hr, O~e 1he ~4 h~um gtef ¢o11~11t 
exposure (p ~ 0.001), Thrum ~ m ~ tugil~lt ~ ~ ~ fl(mH1d 
the s r~J  memase m ~ Cr, 03 ~ 0.6 v~ O.g ± 0,9 mQ~l m me lowest 
,n ~he ~ace~o a~m re~ ~ w,~ a. ~ ~ .avr.g meam.~d 
d ~ pem~ begmm~ at the mn ol am~gmp~ o~ ~me~m 
to ~ a unne go~ ra~e of ~, 145 m~hr m me 24 houm aftra me pm¢e~m, 
Heart Failure: Beta Antagonists 
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Canmdl~l  Inhibits EndoUtelln-1 B lo lyn lheMI  In 
Cu~med Human Coronary Ar~ry ~ l  
EH G~i~,~, G. ~ , / L M .  Romanic, R.R. Ruff~o, Jr.. ~ 
ot Ca,~,~asc~ar P~n~aco~j~, ~ B=~c,~,~ Ptwmz¢e=,¢a~, 
K~ng o~ P~. ,~.  R~ 19406. USA 
It has been m¢~,~-y ~ed thai CHF pa~e~s mm~d ~ car~lo l  have 
s~j~mr~y _r,~,___,c.~__ cmmmm~g ,~-~I  (ET-~) ~ as compared to 
~mm~ed mments. The m~c~ms m p~sma ET-I k.,e*s cormmnmU 
~th a ~ ~ ~ in va~m~ immmemm uud to mea- 
sure the ~ ~ ~ of head P=tiiurB. ~ ,  the f1~ch~-~i~.T~ 
for the ciecmase rn ET-1 was not known Tt-¢=~fore, rne f,,-=s~ s~,~'y was 
des-~g~..d to ~ me d~mct effects of cen~d~m* on ET-I 
5~S in ct.d~fed ~ corollary ~f1~ erl~0~hellal ~ (HCAECs). HCAECa 
were tmaP~J w~h canmd~lol 15 rmn Ire'lot o file ado~itlon of see.~n and ET-1 
levels were measured in the ~.~.~;;~..,,~,.~ mlmlnJ, m 24 hr later. ~ Ira> 
a ~ !  ml~mn of r, emm-med~ 
of ET-I bmsyne~ms ,~th an tC~ = i uM. Pm1~roE'r-1 mRNA e~easmn 
was also mhil~ted by carvedlol maln~nL Oe~r p -adnmo,~v~v a~ago~sls 
such as proprar~ol (10 uM) o~ ce~pm~ol (10 uM) did no~ effect ET.1 
thess. Fu'~e~mmo~, me amh~,~ant IXObUO~ (10 uM) ~ not enect ET-1 
product~n, fo'~muno-hisfochE~cel analys~ of HCAECs silo demonstmtsd 
b~at cenmd~of mh;b;h~3 ET-1 ~ .  These data ~te  thal cenm~Iof 
o~rec~ mhil~s me Im)syne~,s of ET-I in HCAECs, and this effect may 
con1~Imle to its ~,a;.-.;~lat mg and anlqamlifmaftve actions. Fmlhermom. these 
effects may contnbum to the ab~ltty of cantedilof to improve dtnlcal outcome 
in CHF paftents. 
~ Ooes Canmdllol Inhibit Aorlal  Smooth Muscle Cell 
Prol l femtlon? 
P. Mohacsi', K. PI0Ss ~ , HU. Tschanz ~ , S. Gasoflefl I , R. Asm~, 
G. Spon~. ' C ~  U,",tt~t~," ~ Bert,., Gerrp~.t~/; 21.q'Mffu'te of
Biochemistry.. Untversdy of Basel, Germany: ~Boehnnger-Man~ll~m, 
Marmheim. Germany 
Canmdilol [C] is a multiactiog ant]hypertenshte drug recently also apf~oved 
for the treatment of heart failure and combines ~- with a~.bloCking and an- 
tioxidant activities. It was shown that C protects the vasculalum from chronic 
pathological processes such as ischemia, atherosck~osts and remodelling 
that is observed in the cardiovascular system after pressure overload and 
shear stress. To evaluate the antiproliferatwe activity of C on human aofffc 
vascular smooth muscle ceils [SMC], we tested the influence of C and of 
diff ~ ~_nt agents whc'h contnbute to C's activity. SMC were cultured under 
serum free conditions and either treated for 6 hm wffh different cor~-,,;,~- 
tions of C, C's metabofite BM 91.0228 IBM] [without ~.blocldng, but 30.fold 
C 
E 
F 
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increased antloxldent activity], the plain II.blecklng agent Cerazolol [CAR] 
with 8 carbazol moiety (like C), the ~.bleckem Prazoaln [PRA] or Ooxazosln 
[DOX], or the anfioxtdents vltsmln C (VIT C, ascorblc acid) or vitamin E (VIT 
E RRR.~otocopl~erol), The growth factor PDGF was added as a stimulant 
for proliferation (DNA synthesis wna assessed by ~H-thym dine uptake), The 
effect of VIT E w~s measured by using a now technique for cellular VIT E 
loading, 
Results: 
Agent Inhibition f SMC proliferation tIC fin) 
C '1 .reel 
OM 1 ;,reel 
PRA 1-10 ,reel 
I~X 1~10 i,mol 
VIT (~ no inhibition 
VIT ~ no Inhibition 
CAR no Inhlhltlen 
Conclu~ton~: SMC prollteroticn was inhibited by C but not by CAR, Out 
data show that the inhibition of nodal ~MC preltfaration by C is probably d,a 
to Its table,king at i l t  since the tested compounds without ~.hlocking activity 
revealed no Inhibitory affect, St~q~rimngly and In contrast o the literahlre, the 
antlaxldent VIT E did not show an inhibition of SMCs cultured In vitro, 
CMdln© Pred ic tors  o f  T ranap lantet lon :  
Outcome II 
Wednesday, April 1, 1998, Noon-2 :00  p,m, 
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~ Partial In Patients With end Left Ventrlculectomy 
Stage Hur t  Disease - initial Experience 
R,R, Vijayanagar, N, Sears, M, Waston, N, Sastry, B. Master, J, Nareddy, 
G, Chan, Tamp~ G~emf Hospff¢ll, 7hmp~, and Columbia Heart Institu~, 
Humon, Ftor~a, USA 
F~;rpose: To evaluate the Io¢81 experience cf padisl loft ventriculoctomy (PLV) 
for the trsstment of patients with end stage heart disease (ESHD), 
Motheds: 27 ESHD patients (18 males, 9 females: mean ± SD ago 62 
13 years) unde~nt PLV In the period 9/96-7/97, All 27 patients had 
cardlomegaly and 17 pntmnts were ineligible for heart transplantation duo 
to medical contratndic8tions. Idiopathic n:diomyopathy was diagnosed in 
23 patients and lschemtc heart disease ',~s present in 13 patients. Left 
ventricular end-diastolic diameter (LVED) wa~ 7.5 ± 0.9 cm, and election 
fraction was 15 ± 6% peer to surgery. Mit~sl r,~gurgitatlee was present in 26 
p~lienls, and saving tncusp~d regurgitation was documented in 1 indtwdual. 
Concurrent operations performed with PLV Included mttral valve repair in 
10 patients, mltral valve replacement in 16 patients, coronary bypass in 9 
patients, and tdcuspid valve repair =n t patient. Dunng PLV, the rosectod 
ventricular mass was 55 ± 23 grams with moan dimensions of 9.1 cmx 5,6 
cm, 
Resu~: Postoperatively, election fraction increased by 21 ± 10%, and 
LVED decreased by 2.3 ± 1.2 era. Ventricular rupture was not observed. Intra- 
venous inotrepos were required temporarily in all patients due to tow-output 
syndrome, Reversible vontricular tachyarrhythmias occurred in 3 patients, In- 
ducible ventricular ar~hythmia was demonstrated inelectrophysiologic stud- 
los in 2 patients, Transient renal insufficiency was common, though only 1 
individual required dialysis after surgery, Six deaths oocun'od within 30 days 
postoperatively and 4 other patients expired alter the first 30 days, Eight of 
the 10 deaths ace, urinal in patients who were medically ineligible for heart 
transplantation prier to PLV, The romaining 17 patients (63%) remained in 
NYHA functional class It, 
Conclusion: Satisfactory outcome was achievable w=th PLV in ESHD pa- 
tients with dilated cardiomyopathy, including those with concomitant valvular 
and coronary artery lesions. 
~ The Predictive Impact of Abnormalities In 
Ventrlcular Repolarlzatlon on Noncellular 
AIIograft Rejection With Hemodynamlc 
Compromise 
A. Ali, MR. Mehra, F,.~. Malik, F.W. Smart, D.D. Stapleton, K. Ramireddy, 
H.O. Ventt.ra. Ochsner Medical Institutions, New Orleans, Louisiana, USA 
Background: Whether alterations in ventricular epolarization accompany 
hemodynamically significant noncellular (humorel) cardiac allograft rejection 
remains unknown. 
Methods: We Investigated serial changes tn ventriculsr epolarizatlon 
abnormalities by measuring QT dispersion (QT-d) pre, duMng, end tallowing 
recovery from acute allograft dysfunction In 15 he8d transplant recipients 
(ago 49 • 11; 7 men) with acute hemodynamlc ollapse (131 < 2,211minim=), 
evidence of complement and Immunoglobulln deposltlon, end el~er¢o ol 
cellular rejection on endomyo¢ardlal biopsy, QT-d Intervsla ware measured in 
at least 8 of 12 leads of surface EKG obtained prior to, dudng, and foUowing 
recovery after treatment with plasmaphereals, Rata corrected QT¢.d was 
calculated by subtracting the shodest QT-tnterval from the longest interval 
and application of Basalt's formula, 
Results: QTc.d during rejection Increa~e~d significantly trent I~se!lno (76 
~2 vs 58 ± 12; p ,~ 0,01), Similarly, QTc-d r~tum~d fo baseline levels 
following hemodynamie r~'oven/(53 ± 9: p ~ 0,0t), 
% & QTed %, A CI n Valge 
Rejection" +3~ ' .~ 49' 01" 
Recewq/° ~0' *4.0' 06' 
'p .  0.0t; "tampered to h~seline; Scampered !a mleCt~ 
Cenclu,~ions: Alterations in indices O! venfecu!ar opolanzatio~ 
pany acute attograft rejection with hemodynamiG compromise, The close 
association of worsening repalari=ation during mlect~ and nom~!t~aeon 
el these indices with hemodynami~ recovew suggest that assessment el 
repolari,~ation dispersion may serve as a sensitive non.invasive marker ,~l 
resolution o! allogmtl dysfunction, 
~ Effect Anglographl© on o| Abnomtal it les 
Myo0ardlM Padua!on and Resistance in the 
Cardiac AIIograft 
T,J. Donohue, T,L. Wofford, R,G. Bach, E.A. Caracciolo, MJ. Kern, 
L,A. Miller, D.S. Yip, Saint Louis Universt~ USA 
Pathology studies have demonstrated that transplnnt artenopathy invokes 
both epicardial and intramyecardial vessels. Coronary resistance (CR) is 
inversely related to mlcrevascular cross-sectional area and is expected to 
be increased in patients with any ang~ographic abnormalit~s. To assess the 
effect el mild angiograph~c abnormalities on myocardial pedusmn and CR 
post.transplant, we studied 86 allograft recipients with normal eft venmcular 
function and mild (<40% stenosis; abe) of no angiographic ~ ibes  
(norm), Resting (Rest) and hyperemic (HYP) coronary blood flow was mea- 
sured in the LAD, CFX, and RCA (Doppler gutdewire and adenosine). CR 
(dynes,sec.cm -s) and myocardial paffusion (mL/gm.~min) wera calculated 
and normalized for left ventncular mass. Myocardial pedusx~n reserve (MPR) 
= HYP pedusion/resttng peduston. 
N Rest Pod HYP Pod REST CR HYP CR MPR 
Norm (49) t2z05  36± I 217± 110 63±23 33±0.8 
ABN {37) 09,.-03 30t l  267±111" 88 t :~9" 33t08  
"C- O0t v norm 
CR was significantly elevated in the abe group while pedusion was higher 
in the norm group. MPR, however was not different between groups, anC 
thus the degree of microvascular vasedilatory capacity was rdenhcal. This 
suggests no loss of mcrevascular function despite the pmseoce of corrdud 
vessel disease in the cardiac allot]raft. 
~ Effect of Time Post-transplant on Myocardial 
Parfuslon and Coronary Resistance 
T.J. Donohue, T,L. Wollord. LA. Miller, R.G. Bach, E.A. Carecciolo, 
D,S, Yip. Saint Louis Universil}; USA 
A reduced coronanj flow reserve in the early post-transplant poned has 
been described. This was presumed secondary to an eady redaction in mi- 
crovescular vesodilatory capacity and an increast~ in coronary resistance 
(CR). To assess the effect of time post-transplant on pedusion and CR we 
studied 86 cardiac allograft recipients with normal ventncular function and 
mild (~.40% diameter stenosis) or no angiographic abnormalities. Patients 
studied <40 days post.transplant (early) were compared to those studied >_ 1 
year post-transplant (late). Resting (Rest) and hyperemic (HYP) coronary 
blood flow was measured in the LAD, CFX, and RCA (Doppler guidewire 
and adenosine). Myocardial pedusion (mL/gm/min) and coronary resistance 
(dynes.sec -m s) were c~iculated and normalized for left ventricular mass 
at Rest and peak HYP. Myocardial pedusion reserve (MPR) = HYP pedu- 
sign/Rest pedusion. 
N Rest Pad. HYP Pod Rest CR HYP CR MPR 
Early (19) 1.3±0.4 3.7±1 181:1:77 63±19 2.6+0.5 
Late (67) 1.0 ± 0.4" 3.3 • 1 207 ± 118" 77 ± 29 3.5 ± 0.8" 
"p < 0.001 v. early 
